Navigation Links
CNS Response, Inc. Names William E. Bunney, Jr., MD to Scientific Advisory Board
Date:5/5/2008

COSTA MESA, Calif., May 5 /PRNewswire-FirstCall/ -- CNS Response, Inc. (OTC Bulletin Board: CNSO) announced today that it has appointed William E. Bunney, Jr., MD to its Scientific Advisory Board. Dr. Bunney is Senior Associate Dean for Research and Distinguished Professor, Department of Psychiatry and Human Behavior, School of Medicine, University of California, Irvine.

Len Brandt, Chairman and CEO of CNS Response, reported, "Considering Dr. Bunney's distinguished career and his position as a thought leader in psychiatry, we are honored that he has accepted a position on our Scientific Advisory Board. His informal counsel has been very valuable to CNS Response during the past year. I am certain that Dr. Bunney's continued input will benefit CNS Response's mission to provide physiological guidance to treatment."

In addition to his position at the University of California, Irvine, Dr. Bunney has held key appointments with several prominent government institutions and research organizations focused on mental health and behavioral sciences-related issues. Among his affiliations, Dr. Bunney currently serves on the Scientific Advisory Boards of the Harvard International Brain Repository and the World Health Organization (WHO) Expert Panel on Mental Health, was previously the Director of the Federal Treatment, Education and Research Endeavor for Narcotic Addiction and Drug Abuse with the National Institutes of Health, and was elected to the Institute of Medicine of the National Academy of Sciences where he was designated a Lifetime National Associate. Dr. Bunney has also served as President of four research organizations: American College of Neuropsychopharmacology, CINP, West Coast College of Biological Psychiatry, and Psychiatric Research Society.

Dr. Bunney received his M.D. from the University of Pennsylvania Medical School and completed his residency in Psychiatry at Yale University School of Medicine. He is the author of more than 390 scientific publications and the editor of seven books.

About CNS Response

CNS Response is a life-sciences data company whose patented system provides treatment guidance to psychiatrists and other physicians for patients with behavioral (mental or addictive) disorders. This technology allows CNS Response to create and provide simple reports ("rEEG(R) Reports") that specifically guide physicians to treatment strategies based on the patient's own physiology.

rEEG(R) utilizes traditional electroencephalography (EEG) in conjunction with a normative database and a proprietary clinical (symptomatic) database to identify the following: (1) medication classes most likely to be needed; and (2) medications within these classes with the most probable treatment potential for each patient. Reports are provided to physicians in a relationship analogous to that of a reference laboratory. Prospective, retrospective and field studies of treatment-resistant patients have reported treatment success of 70% or greater in managed care, outpatient psychiatric and residential substance abuse clinical settings.

In addition to providing analytical support to physicians, CNS Response is also an aid to pharmaceutical developers, who can use rEEG to (1) stratify study populations to improve the success of FDA clinical trials; (2) provide insight on effective therapeutic dosing of investigational drugs; (3) identify additional indications for psychiatric medications; (4) provide insight into effective drug combinations; and (5) discover opportunities for decision analytics and support. In addition to these applications, CNS Response continues to investigate the use of rEEG analysis for development of proprietary pharmaceutical opportunities.

Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995

Except for the historical information contained herein, the matters discussed are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, as amended. These statements involve risks and uncertainties as set forth in the Company's filings with the Securities and Exchange Commission. These risks and uncertainties could cause actual results to differ materially from any forward-looking statements made herein.

Contacts:

Investor Relations:

Sara Ephraim

(646) 536-7002

sephraim@theruthgroup.com

Media:

Jason Rando / Jennifer Saunders

(646) 536-7033 / 7011

jrando@theruthgroup.com

jsaunders@theruthgroup.com


'/>"/>
SOURCE CNS Response, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. CNS Response, Inc: rEEG(R) Research to be Presented at 38th National Council Conference
2. CNS Response, Inc. Enters Agreement to Introduce rEEG(R) Platform to Managed Behavioral Health Organization
3. Bacterial toxin closes gate on immune response, Penn researchers discover
4. CNS Response, Inc. Names Henry T. Harbin, MD to Board of Directors
5. CNS Response, Inc. Modifies rEEG(SM) Trial Protocol for Treatment-Resistant Depression Study
6. CNS Response, Inc. Appoints George C. Carpenter IV to Position of President
7. AACN Names 2008 Circle of Excellence Award Recipients
8. Cosmetic Bootcamp Announces Record Attendance and Sponsorship and Names Members of Its Board of Advisors
9. PEMCOs Super-Long-Coffee-Order Contest Names Newest Winners
10. Ventas Names Chicago as Headquarters
11. SCA Names Andrew Hayek as New President and CEO
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... , ... Austin residents seeking Mohs surgery services, can now turn to Dr. ... Russell Peckham for medical and surgical dermatology. , Dr. Dorsey brings specialization to include ... in Mohs Micrographic Surgery completed by Dr. Dorsey was under the direction of Glenn ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin Johnson has ... he has implemented orthobiologic procedures as a method for treating his patients. The ... first doctors to perform the treatment. Orthobiologics are substances that orthopaedic surgeons use ...
(Date:6/24/2016)... ... June 24, 2016 , ... June 19, 2016 is World Sickle ... chronic pain and the benefits of holistic treatments, Serenity Recovery Center of ... Sickle Cell Disease. , Sickle Cell Disease (SCD) is a disorder of the red ...
(Date:6/24/2016)... ... June 24, 2016 , ... Comfort Keepers® of San Diego, CA is excited ... To Recovery® program to drive cancer patients to and from their cancer treatments. ... highest quality of life and ongoing independence. Getting to and from medical treatments ...
(Date:6/24/2016)... ... June 24, 2016 , ... Puradigm® & Innovative Solutions today ... cultivation and processing operations at its production facility, and opened its first two ... the manufacturer of a complete system of proactive air and surface purification solutions ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... Research and Markets has ... 2015-2025: Applications, Technologies, Forecasts" report to their ... Electronics, Smart Skin, Structural Health Monitoring, Composite Smart ... electronics involves electronic and/or electrical components and circuits ... structures such as vehicle bodies or conformally placed ...
(Date:6/24/2016)... and SAN CLEMENTE, Calif. , June 24, ... -based mobile pulmonary function testing company, is now able to perform ... developed by ndd Medical Technologies , Inc. ... in hospital-based labs.  Thanks to ndd,s EasyOne PRO ® , ARL ... can get any needed testing done in the comfort of her ...
(Date:6/24/2016)... 2016   Pulmatrix, Inc ., (NASDAQ: ... drugs, announced today that it was added to the ... its comprehensive set of U.S. and global equity indexes ... important milestone for Pulmatrix," said Chief Executive Officer ... our progress in developing drugs for crucial unmet medical ...
Breaking Medicine Technology: